These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8571103)

  • 1. [Mumps: efficacy of booster immunization].
    Gassner M; Hess U; Berger R
    Schweiz Med Wochenschr; 1995 Dec; 125(51-52):2506-10. PubMed ID: 8571103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.
    Ong G; Goh KT; Ma S; Chew SK
    J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.
    Rubin SA; Qi L; Audet SA; Sullivan B; Carbone KM; Bellini WJ; Rota PA; Sirota L; Beeler J
    J Infect Dis; 2008 Aug; 198(4):508-15. PubMed ID: 18558869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mumps epidemic in vaccinated children in West Switzerland].
    Ströhle A; Eggenberger K; Steiner CA; Matter L; Germann D
    Schweiz Med Wochenschr; 1997 Jun; 127(26):1124-33. PubMed ID: 9312835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rubini, a new live attenuated mumps vaccine virus strain for human diploid cells.
    Glück R; Hoskins JM; Wegmann A; Just M; Germanier R
    Dev Biol Stand; 1986; 65():29-35. PubMed ID: 3556774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Estimation of the efficacy of three strains of mumps vaccines during an epidemic of mumps in the Geneva canton (Switzerland)].
    Chamot E; Toscani L; Egger P; Germann D; Bourquin C
    Rev Epidemiol Sante Publique; 1998 Mar; 46(2):100-7. PubMed ID: 9592852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian expanded programme on immunization.
    Avijgan M; Habibian R; Kheiri S
    East Mediterr Health J; 2009; 15(2):295-301. PubMed ID: 19554975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on live attenuated mumps vaccine. II. Follow-up study on the efficacy of Biken Vaccine.
    Isomura S; Ozaki T; Morishima T; Nagayoshi S; An S
    Biken J; 1976 Sep; 19(3):115-8. PubMed ID: 1016214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of immunity four years following Jeryl Lynn strain live mumps virus vaccine.
    Weibel RE; Buynak EB; Stokes J; Hilleman MR
    Pediatrics; 1970 May; 45(5):821-6. PubMed ID: 5444402
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccination of school children with live mumps virus vaccine.
    Furesz J; Nagler FP
    Can Med Assoc J; 1970 May; 102(11):1153-5. PubMed ID: 5420994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.
    LeBaron CW; Forghani B; Beck C; Brown C; Bi D; Cossen C; Sullivan BJ
    J Infect Dis; 2009 Feb; 199(4):552-60. PubMed ID: 19113988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemagglutinin-neuraminidase sequence and phylogenetic analyses of mumps virus isolates from a vaccinated population in Singapore.
    Lim CS; Chan KP; Goh KT; Chow VT
    J Med Virol; 2003 Jun; 70(2):287-92. PubMed ID: 12696120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Jeryl Lynn-containing vaccine in Spanish children.
    Castilla J; García Cenoz M; Arriazu M; Fernández-Alonso M; Martínez-Artola V; Etxeberria J; Irisarri F; Barricarte A
    Vaccine; 2009 Mar; 27(15):2089-93. PubMed ID: 19356610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A five-year observation on efficacy of revaccination in children of non-response to hepatitis B vaccine].
    Zhuang GH; Yan H; Wang XL; Wu Q; Wang LR; Gao HY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2006 Jan; 40(1):8-12. PubMed ID: 16620590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacy of various strains of mumps vaccine: a school survey].
    Toscani L; Batou M; Bouvier P; Schlaepfer A
    Soz Praventivmed; 1996; 41(6):341-7. PubMed ID: 9027138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.